Clinical Study
Endothelial Dysfunction in Cystic Fibrosis: Role of Oxidative Stress
Table 2
Parameters of the FMD test in patients with CF completing the AOC treatment (CF-AOC; ), placebo condition (CF-PLC; ), or healthy controls ().
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Values are the . FMD = flow-mediated dilation. Significant pre- to posttreatment change versus CF-PLC (); †significant difference versus Pre in CF-AOC (); ‡significant difference versus Pre in CF-PLC (). |